We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
-12.68%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$1.68B
AUM Growth
-$191M
Cap. Flow
+$173M
Cap. Flow %
10.28%
Top 10 Hldgs %
55%
Holding
67
New
15
Increased
26
Reduced
11
Closed
7

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$53.6M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$31.7M
3
BLU
BELLUS Health Inc.
BLU
+$29.5M
4
DMTK
DermTech, Inc. Common Stock
DMTK
+$28.5M
5
PTCT icon
PTC Therapeutics
PTCT
+$22.4M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$34.1M
2
ILMN icon
Illumina
ILMN
+$30.2M
3
ARWR icon
Arrowhead Research
ARWR
+$29.7M
4
KIDS icon
OrthoPediatrics
KIDS
+$14.7M
5
MYGN icon
Myriad Genetics
MYGN
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 94.09%
2 Communication Services 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARVN icon
26
Arvinas
ARVN
$542M
$17.4M 1.04%
809,623
+1,753
+0.2% +$43K
AXSM icon
27
Axsome Therapeutics
AXSM
$11B
$17.1M 1.02%
846,121
+1,832
+0.2% +$47.1K
JNJ icon
28
Johnson & Johnson
JNJ
$621B
$15.1M 0.9%
116,858
+22,946
+24% +$3.02M
MDXG icon
29
MiMedx Group
MDXG
$606M
$14.5M 0.86%
+2,964,000
New +$14.5M
CSTL icon
30
Castle Biosciences
CSTL
$929M
$13.5M 0.8%
+745,045
New +$16.5M
DMTK
31
DELISTED
DermTech, Inc. Common Stock
DMTK
$12.5M 0.74%
+2,386,871
New +$28.5M
TMDX icon
32
Transmedics
TMDX
$2.64B
$12M 0.71%
503,266
-3,741
-0.7% -$89.7K
QDEL icon
33
QuidelOrtho
QDEL
$1.19B
$10.8M 0.64%
+176,495
New +$10.6M
RGNX icon
34
Regenxbio
RGNX
$672M
$10.4M 0.62%
291,168
-76,872
-21% -$3.11M
QTNT
35
DELISTED
Quotient Limited Ordinary Shares
QTNT
$9.95M 0.59%
32,029
-6,572
-17% -$2.53M
LAB icon
36
Standard BioTools
LAB
$307M
$9.77M 0.58%
2,109,500
+32,029
+2% +$252K
NTRA icon
37
Natera
NTRA
$39.3B
$9.43M 0.56%
+287,470
New +$8.5M
PTGX icon
38
Protagonist Therapeutics
PTGX
$8.83B
$9.15M 0.54%
+762,283
New +$9.61M
ODT
39
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$8.85M 0.53%
339,892
+736
+0.2% +$24.6K
ABUS icon
40
Arbutus Biopharma
ABUS
$913M
$8.48M 0.5%
5,562,967
+29,874
+0.5% +$51.5K
SILK
41
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$7.96M 0.47%
244,716
+20,994
+9% +$836K
XGN icon
42
Exagen
XGN
$161M
$7.92M 0.47%
+511,633
New +$8.26M
PRNB
43
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$7.65M 0.46%
270,948
– –
BWAY
44
Brainsway
BWAY
$602M
$7.6M 0.45%
1,669,374
+474,942
+40% +$2.38M
CTMX icon
45
CytomX Therapeutics
CTMX
$729M
$7.31M 0.43%
990,463
+2,144
+0.2% +$21.1K
CHAC.U
46
DELISTED
Chardan Healthcare Acquisition Corp.
CHAC.U
$7.18M 0.43%
600,000
– –
QURE icon
47
uniQure
QURE
$3.07B
$5.7M 0.34%
144,909
+314
+0.2% +$18.1K
INMD icon
48
InMode
INMD
$874M
$5.38M 0.32%
+500,000
New +$5.7M
VIRX
49
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$5M 0.3%
+198,459
New +$5.73M
PSNL icon
50
Personalis
PSNL
$1.44B
$3.74M 0.22%
255,000
+30,000
+13% +$567K
1
2
3

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $9.92B AUM 21.52% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return

RTW Investments's Q3 2019 Portfolio in Review

As of Q3 2019, RTW Investments held 67 positions worth $1.68B, down 10% from $1.87B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

RTW Investments deployed $173M of net new capital in Q3 2019, opening 15 new positions and adding to 26 existing holdings. Its largest new stake was Zimmer Biomet: 415,090 shares worth $55.3M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 94% a quarter earlier, followed by Communication Services.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $34.1M trimmed.

  • RTW Investments's largest Q3 2019 buy was Zimmer Biomet: 415,090 shares worth $55.3M.
  • RTW Investments added most to Mirati Therapeutics, Inc. Common Stock in Q3 2019, an estimated $31.7M increase.
  • RTW Investments's biggest Q3 2019 reduction was Alnylam Pharmaceuticals, cutting an estimated $34.1M.
  • RTW Investments fully exited Illumina in Q3 2019, selling an estimated $30.2M.
  • RTW Investments's ten largest holdings make up 55% of its $1.68B portfolio in Q3 2019.
  • RTW Investments opened 15 new positions and closed 7 in Q3 2019.
  • RTW Investments's portfolio value fell 10% quarter-over-quarter to $1.68B.

Based on RTW Investments's 13F filing for Q3 2019, filed 14 Nov 2019.